C WorldWide Group Holding A S reduced its position in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 7.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,010 shares of the specialty pharmaceutical company’s stock after selling 17,011 shares during the period. C WorldWide Group Holding A S’s holdings in Valeant Pharmaceuticals International were worth $3,408,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of VRX. Gruss & Co. Inc. acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter worth about $104,000. Financial Architects Inc raised its position in shares of Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares during the period. Harbor Advisors LLC acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter worth about $110,000. WMS Partners LLC acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter worth about $116,000. Finally, Brave Asset Management Inc. acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter worth about $119,000. 51.14% of the stock is owned by institutional investors and hedge funds.

Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at 13.89 on Friday. Valeant Pharmaceuticals International, Inc. has a 12-month low of $8.31 and a 12-month high of $32.74. The stock’s market cap is $4.83 billion. The stock has a 50 day moving average price of $16.57 and a 200-day moving average price of $13.38.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The company had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. During the same quarter in the previous year, the business earned ($0.88) EPS. The firm’s revenue was down 7.7% on a year-over-year basis. Equities analysts anticipate that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Stake Reduced by C WorldWide Group Holding A S” was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/12/valeant-pharmaceuticals-international-inc-nysevrx-stake-reduced-by-c-worldwide-group-holding-a-s.html.

VRX has been the subject of a number of recent analyst reports. Jefferies Group LLC set a $18.00 price objective on Valeant Pharmaceuticals International and gave the stock a “buy” rating in a report on Saturday, May 6th. Stifel Nicolaus reissued a “buy” rating and issued a $45.00 price objective on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. Vetr lowered Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.94 price objective for the company. in a report on Monday, May 15th. Guggenheim initiated coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, BidaskClub raised Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a report on Thursday, June 29th. Four research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $17.31.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.